Akari Therapeutics, Plc (AKTX)
AKTXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$7.20
-0.6301 (-8.05%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $17.02m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.02 to $29.32
- Average volume
- 63.0k
- Previous close
- $7.83
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $25.50, +254.2% from here
Earnings
Next report Nov 12, 2026
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$7.40m | -$3.23m | -$15.76m | -$4.60m |
| Net income | -$6.40m | -$5.30m | -$14.46m | -$4.81m |
News
8 latest- Akari Therapeutics Seeks To Address ADC Resistance With Novel PH1 Payload; Stock Up RTTNews · Oct 15, 2026
- Akari Expands IP Portfolio With PCT Filing For PH1 ADC Payload RTTNews · Oct 1, 2026
- Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories RTTNews · Aug 29, 2026
- Akari Reports Preclinical Activity For AKTX-101 In Urothelial Cancer Model RTTNews · Aug 18, 2026
- Akari Enters Strategic Research Collaboration With Whitehawk To Advance ADC Innovation; Stock Down RTTNews · Jul 21, 2026
- Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics, Stock Down RTTNews · Jul 21, 2026
- Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest RTTNews · May 29, 2026
- Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch RTTNews · May 26, 2026
The company
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Europe
- Website
- akaritx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.